Racing: Victoria beefs up drug testing, security policy

MELBOURNE - Security will be provided to all group one runners in the lead-up to race time under a new policy announced as part of a raft of integrity initiatives to be implemented by Racing Victoria Limited (RVL).

RVL has strengthened its commitment to higher integrity standards with a series of measures focused on improved drug control and compliance monitoring, investment in drug research and the expansion of resources devoted to bookmaker and wagering operator supervision.

Surveillance of all group one runners will be organised from 6pm on the eve of all elite races in Victoria and other selected races identified by the stewards.

Earlier this year security was placed on runners before the Australian Cup won by Makybe Diva.

Other specific integrity measures to enhance drug controls include:-

* A 75 per cent increase in the number of horses sampled pre-race and 50 per cent post-race;

* The development and implementation of a sophisticated computer database using risk analysis techniques for targeted sampling of horses;

* Provision of more than A$600,000 over the next three years for the Racing Analytical Services Laboratory to upgrade analytical equipment to significantly enhance screening capabilities;

* A review of processes relating to raceday horse arrival requirements on course at metropolitan and country meetings;

* The creation of a dedicated unit of three stewards and investigators focused on stable inspections, and non-raceday drug testing;

* Implementation of changes to the analytical methodologies employed in pre-race blood screening to significantly enhance effectiveness, and,

* Support for the tri-code submission to the state government for funding of a significantly expanded drug research programme.

The changes follow a review of all aspects of drug control and management which included discussions with trainers and owners.

RVL's director of veterinary services John McCaffrey said the enhancements would position Victorian racing as a world leader.

"Ongoing investment in drug research and constantly upgrading our technology, systems and equipment will further strengthen our ability to be at the cutting edge of detection and surveillance," McCaffrey said.